Sandoz US News
Sandoz today announced the signing of an exclusive license and supply agreement with BioQuiddity Incorporated, a specialty pharmaceutical company, under which Sandoz has the right to market Under the agreement, BioQuiddity is responsible for obtaining the requisite regulatory approvals and supplying the unit-dose infusion systems, and Sandoz is responsible for marketing and commercializing the products. Financial details of the agreement were not disclosed.
Sandoz receives FDA approval for GlatopaTM as the first generic competitor to MS therapy Copaxone® 20mg
FDA approves first biosimilar Zarxio™ (filgrastim-sndz) from Sandoz
Visit our multimedia gallery to learn about Sandoz.
Use our Product Catalog tool to search our database for information regarding a specific Sandoz product in the US.
Click below for important links.
Our people are our greatest resource. We are always looking for new colleagues to share in our passion and commitment to making the world a healthier place.
Sandoz is a world leader in generic pharmaceuticals, providing access to a wide array of high-quality, affordable medicines. In the US, Sandoz markets more than 200 different generic drugs, including enoxaparin sodium injection, the first generic version of Lovenox®, and Omnitrope®, the groundbreaking follow-on biologic. Our 2,300 US associates are proud to make Sandoz a "healthy decision."
As part of the Novartis group, we believe that superior quality is the key to our long-term success. Our state-of-the-art technologies, decades of experience, and rigorous across-the-board quality standards all contribute to our broad portfolio of premium quality generic medicines.
We use innovation and expertise to go beyond standard generics and develop even the most complex medicines, which add value to patient healthcare – from generic injectables and ophthalmics to biosimilars and respiratory. Driving patient access to cost-effective treatment is how we are shaping the future of healthcare.
Sandoz was the first company to develop and market follow-on versions of highly-complex biopharmaceuticals. Today, we are the undisputed global leader in this segment and have an industry-leading pipeline that will make essential biologics more affordable for all.